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Abstract
Background: Essential medicines (EMs) are those medicines which satisfy the priority health care needs of the
population. Although it is a fundamental human right, access to essential medicines has been a big challenge in
developing countries particularly for children. WHO recommends assessing the current situations on availability and
affordability of EMs as the first step towards enhancing access to them. Therefore, the aim of this study was to
assess access to EMs for children based on availability, affordability, and price.
Methods: We adapted the WHO and Health Action International tools to measure availability, affordability, and
prices of EMs. We collected data on 22 EMs for children from 15 public to 40 private sectors’ drug outlets in east
Wollega zone. Availability was expressed as percentage of drug outlets per sector that stocked surveyed medicines
on the day of data collection, and prices were expressed as median price ratio. Affordability was measured as the
number of daily wages required for the lowest-paid government unskilled worker (1.04 US $per day) to purchase
one standard treatment of an acute condition or treatment for a chronic condition for a month.
Results: The average availability of essential medicines was 43 % at public and 42.8 % at private sectors. Lowest
priced medicines were sold at median of 1.18 and 1.54 times their international reference prices (IRP) in the public
and private sectors, respectively. Half of these medicines were priced at 0.90 to 1.3 in the public sector and 1.23 to
2.07 in the private sector times their respective IRP. Patient prices were 36 % times higher in the private sector than
in the public sector. Medicines were unaffordable for treatment of common conditions prevalent in the zone at
both public and private sectors as they cost a day or more days’ wages for the lowest paid government unskilled
worker.
Conclusions: Access to EMs to children is hampered by low availability and high price which is unaffordable. Thus,
further study on larger scale is critical to identify acute areas for policy interventions such as price and or supply,
and to enhance access to EMs to children.
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Background
Essential medicines (EMs), which satisfy the priority
health care needs of the population, are backbone of
health care and well being of individuals and populations
[1–3]. Access to health care including EMs is a funda-
mental human right [4, 5]. However, access to EMs has
been a big challenge particularly in developing countries
where more than half of their populations lack access to
EMs [6] and majority of them are children [7].
Access to EMs is influenced by many interlinked fac-
tors such as the availability of medicines in the health
care facilities, availability of sustainable financing and
reliable health systems, rational selection and use of
medicines, and affordable price [1, 8, 9]. In addition to
these factors, they are also hardly found in the health
care facilities in the recommended dosage for children
[10, 11]. This shows the inaccessibility of EMs for
children in the developing countries where majority of
child mortality is due to treatable diseases [10, 12]. This
is also true for Ethiopia, where more than 60 % of child
deaths are due to communicable diseases [13].
In order to escalate the accessibility of EMs for children,
World Health Organization (WHO) developed Essential
Medicine Lists for children (EMLc) in 2007 and it has also
been promoting to formulate medicines in line with child
body size through “make medicine child size” initiative
[10, 14]. The initiative aims to enhance the accessibility of
safe, effective and quality medicines for children by pro-
moting awareness and action through research, regulatory
measures and changes in policy [10]. In line with the ini-
tiative, measuring the availability and prices of essential
medicines in all sectors is a vital step to improve the ac-
cessibility of EMs for children [10].
Data on the availability and affordability of EMs help
managers and policy makers to develop national policy,
regulations and strategies to enhance access to them. How-
ever, there are fewer studies which provide these types of
data for managers and policy makers. A study conducted
on the availability and prices of the WHO’s EMs for chil-
dren in Guatemala revealed that availability of EMs is less
than 50 % in both private and public sectors, and prices for
both lower priced medicines and higher priced medicines
are higher than the respective international reference
prices (IRP) and unaffordable, costing as much of 15 days’
wages [10]. Similar finding is reported from the studies
conducted in China [15, 16]. There is also a survey con-
ducted in fourteen central Africa countries which showed
poor availability of EMs for children in both private and
public sectors, and higher prices with considerable varia-
tions [17]. A national study conducted by Abiye and his
colleagues in the western part of Ethiopia showed that
availability of medicine is almost higher than 50 %, and
medicines are sold at average of 0.65 and 0.94 times the
IRP in the public and private sectors, respectively [18].
Although limited access to EMs for children is a global
problem [19, 20], it is pressing issue in developing coun-
tries particularly for Sub-Sahara Africa countries [21].
Beyond that, the extent of the problem in Ethiopia is un-
known. To the authors’ best knowledge, the previous
study on the availability and affordability of EMs in the
western part of Ethiopia [18] only focused on the medi-
cines for adult, and it was also not conducted according
to WHO/Health Action International (HAI) method-
ology. So, there has been no study conducted on the
availability and affordability of EMs for children in
Ethiopia. Therefore, the purpose of this study was to
assess the availability, prices and affordability of EMs for
children to determine their accessibility for children.
Methods
Study area and design
A drug outlets based cross-sectional study was con-
ducted in east Wollega zone, western part of Ethiopia.
Data on the availability and prices of 22 EMs for
children were collected in January, 2015 by adapting of
the WHO/HAI standardized methodology [22].
Selection of drug outlets
Ten districts were randomly selected from the seventeen
districts found in the east Wollega zone. There were a
total of 56 drug outlets found in the ten selected districts
surrounding Nekemte town, the capital city of the zone,
and 40 drug outlets in the Nekemte town. These drug
outlets were stratified into public, private and other
(NGO drug outlets) sectors. From public sector, at least
one drug outlet per district was randomly selected and
included, but one hospital pharmacy, found in the sur-
rounding district, was included purposely according to
WHO/HAI recommendation [22]. From private sector,
at least two drug outlets per district were randomly se-
lected and included in the study. Private drug outlets
were selected at a ratio of 2:1 compared to public drug
outlets because the number of private drug outlets is 2–5
times higher than public drug outlets in the selected
districts, and private outlets serve as major sources of
drugs for the public. However, all drug outlets of other
sector found in the surrounding districts and the town
were included purposely. We also included all three
public drug outlets and one hospital pharmacy found in
the town, purposely. Among 40 private outlets found in
the town, 22 drug outlets were randomly selected and
included in the study.
Selection of medicines
Twenty three EMs were identified based on the core list
of the WHO EMLc specified by the “Better Medicines
for Children Project” effort [23] and prevalence of dis-
eases associated with childhood illness in the zone [East
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Wollega Health Department]. For each surveyed medi-
cine, we collected data on the lowest priced, highest
priced (instead of innovator/brand medicines), and its
availability. But for antimalaria medicines, vitamin A and
Zinc which are free of charge for public at public sector,
we checked only their availability.
Data collection and analysis
We collected data on the availability and patient prices
of medicines from 58 drug outlets during January, 2015.
Among 58 drug outlets, 15 were from the public sector,
41 were from the private sector and two were from the
other sector. Five data collectors were recruited and
trained according to WHO/HAI methodology and pre-
test was conducted in Ghimbi town, as it has close
geographic proximity and population with similar socio-
economic status, and similar distribution of drug outlets.
The data collectors collected information on availability
and price using a standard data collection format spe-
cific to the EMs under survey Additional file 1. Then,
”we entered data into the pre-programmed MS Excel
Workbook provided as part of the WHO/HAI method-
ology” [22]. Data were double entered, cleared and
analysed by using MS Excel Workbook provided by
WHO/HAI Management Sciences for Health (MSH)
2012 part I. We presented the results by using tables
and bar chart.
Though data were collected from 58 drug outlets, we
analysed only the data collected from 55 drug outlets
where 15 of them were from the public sector and 40 were
from the private sector. We excluded data collected from
one private drug outlet because the collected information
was incomplete. Two drug outlets from other sector were
also excluded as they do not fulfill the WHO/HAI recom-
mendation criteria; the minimum number of drug outlets
per sector should be four or greater than four [22].
Among the twenty three surveyed drugs, we included
only twenty two drugs in analysis for both public and
private sectors (Table 1). We excluded phenobarbitone
(Phenobarbital) 20 mg/5 ml elixir from analysis as the
information was not yet collected because wrong tar-
geted pack size was used in data collection formats.
Measuring availability and affordability of medicines
We used IRP of 2014 given by Management Sciences for
Health (MSH) to facilitate national and international
Table 1 Lists of medicines surveyed in east Wollega zone
No Name Strength Dosage form Indications
1. Amoxicillin 125 mg/5 ml Suspension Infectious disease
2. Amoxicillin 250 mg/5 ml Suspension Infectious disease
3. Amoxicillin + Clavulanic Acid 125 mg + 31.25 mg/5 ml Suspension Infectious disease
4. Amoxicillin + Clavulanic Acid 250 mg + 62.5 mg/5 ml Suspension Infectious disease
5. Artesunatea 60 mg Vial Infectious disease
6. Artemether + Lumefantrinea 20 mg + 120 mg Dispersible tab. Infectious disease
7. Chloramphenicol 1 gm Vial Infectious disease
8. Carbamazepine 100 mg/5 ml Syrup Seizure disorder
9. Ceftriaxone 500 mg Vial Infectious disease
10. Cotrimoxazole 40 mg + 200 mg/5 ml Suspension Infectious disease
11. Diazepam 5 mg/ml Ampoule Seizure disorder
12. Gentamicin 20 mg/2 ml Ampoule Infectious disease
13. Ibuprofen 100 mg/5 ml Suspension Pain/inflammation
14. ORS To make 500 ml Powder Dehydration
15. Paracetamol 120 mg/5 ml Syrup Pain
16. Paracetamol 125 mg Suppository Pain
17. Penicillin G 1 million IU Vial Infectious disease
18. Procaine Penicillin G 4 million IU Vial Infectious disease
19. Salbutamol 100 mcg/dose Inhaler Asthma
20. Vitamin Aa 50,000 units Capsule Xerophthalmia
21. Zinc Phosphatea 20 mg Dispersible tab Dehydration
22. Procaine Penicillin G 4 million IU Vial Infectious disease
aMedicines free of charge to the public in the public sector
ORS oral rehydration salt
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comparisons. The MSH reference prices are the medians
of recent procurement prices offered for generic prod-
ucts by not-for-profit suppliers to developing countries
[24]. For cross-country comparisons purpose, we
expressed prices as median price ratios (MPR). MPR is
ratio of median local unit price relative to IRP [10]:
MPR ¼ Median:local:unit:price
International:reference:unit:price
We calculated MPR only for medicines with price data
obtained from at least 4 drug outlets according to
WHO/HAI recommendation. We used 1 US$ = 19.6758
Ethiopian Birr exchange rate to calculate MPR, and it
was commercial buying rate obtained from www.com-
banketh.et/currencyrate on the first day of data collec-
tion [25].
We measured availability by physical presence of EMs
in the drug outlets on single visit during data collections.
We expressed it as percentage of sampled drug outlets
that have a particular EMs [26].
We assessed affordability for a standard treatment of
top ten prevalent diseases in the childhood by compar-
ing the total price of medicine at a standard dose ac-
cording to Ethiopian standard treatment guideline for
pediatrics to the daily wage of the lowest paid government
unskilled employee at 20.5 Ethiopian birr (1.04 US $) per
day at the time of data collection. The cost of medicine
for a full course of therapy for acute diseases and a 30-
days’ supply of medicines for chronic diseases was
calculated and changed to the day wage. Even though it
is difficult to assess the real affordability of the medi-
cine, we categorized as a medicine affordable “if it costs
less than a day wage and unaffordable if it costs a day
wage or more than a day wages” [10].
Ethical considerations
The study protocol was reviewed and approved by
Institutional Research Review Committee of College of
Medical and Health Sciences, Wollega University. The
owners of drug outlets who participated were informed
of the aims of study prior to participation, and a verbal
consent was sought from each participated owner of
drug outlet after explaining his/her right not to partici-
pate into the study. They were assured of confidentiality
on the issues related to the business secret of premises
by avoiding identifiers from the data collection tools.
Results
Availability of medicines on the day of data collection
The results as shown in Table 2 revealed that the avail-
ability of lowest priced individual medicines varied by
type of medicine and sector. It was found that average
availability of the highest priced medicines was 1.2 %
(range 0–4.5 %) and 43.0 % (range 10.7–75 %) for the
lowest priced medicines in the public sector. Average
availability in the private sector was 7.4 % (range 0–
18.3 %) for the highest priced medicines and 42.8 %
(range 6.5–77.1 %) for lowest priced medicines.
In the public drug outlets, generic medicines were
the predominant product type available with 96 % of
medicines found as generics. Although vitamin A, zinc
phosphate and antimalaria medicines are expected to
be available in the public sector only, some of them
such as artesunate (26.7 %) and vitamin A (20 %) had
low availability. Carbamazepine 100 mg/5 ml syrup, di-
azepam 5 mg/ml ampoule, gentamicin 20 mg/2 ml am-
poule and ibuprofen 100 mg/5 ml suspension were not
found in any drug outlets in both public and private
sectors. The average availability of individual lowest
price medicines in both public and private sectors was
shown in Table 2.
Table 2 Average availability of individual lowest priced
medicines in the public and private sectors
Name of medicine Percentage of outlets where
medicine was found
Public sector
(n = 15 outlets)
Private sector
(n = 40 outlets)
Amoxicillin Suspension 125 mg 80 % 90 %
Amoxicillin Suspension 250 mg 60 % 80 %
Amoxicillin- Clava Suspension 125 mg 66.7 % 47.5 %
Amoxicillin- Clava Suspension 250 mg 13.3 % 40 %
Artesunate 60 mg vial 26.7 % 0.0 %
Artemether + Lumefantrine
20 mg + 120 mg disp. tab
66.7 % 0.0 %
Chloramphenicol 1gm vial 46.7 % 20 %
Carbamazepine 100 mg/5 ml syrup 0.0 % 0 %
Ceftriaxone 500 mg vial 26.7 % 22.5 %
Cotrimoxazole 40 mg + 200 mg/5 ml
suspension
100 % 90 %
Diazepam 5 mg/ml ampoule 0.0 % 0.0 %
Gentamicin 20 mg/2 ml ampoule 0.0 % 0.0 %
Ibuprofen 100 mg/5 ml Suspension 0.0 % 0.0 %
ORS to make 500 ml soln. 0.0 % 2.5 %
ORS to make 1000 ml soln. 40 % 87.5 %
Paracetamol 120 mg/5 ml Syrup 93.3 % 80 %
Paracetamol 125 mg Suppository 93.3 % 87.5 %
Penicillin G 1million IU vial 46.7 % 12.5 %
Procaine Penicillin G 4 million IU vial 40 % 57.5 %
Salbutamol 100 mcg/dose inhaler 46.7 % 52.5 %
Vitamin A 50,000 units Cap. 20 % 0.0 %
Zinc Phosphate 66.7 % 0.0 %
Clava: − Clavulanic acid/Clavunate
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Costs of medicines in public and private sectors
To assess price variation of individual medicine across
sectors, we calculated MPR of 13 (n = 13) lowest priced
medicines. As shown in Table 3, MPR for lowest price
medicines were found to be 1.18 times their IRP in the
public sector. MPR for patient prices ranged from 0.58
to 2.86 times the IRP in the public sector for paraceta-
mol suppository and penicillin G injection respectively.
Half of lowest priced medicines were priced at 0.90 (25th
percentile) to 1.3 (75th percentile) times their IRP in the
public sector, showing small variation within sector.
In the private sector, MPR for lowest priced medicines
were found to be 1.54 times their IRP, and patient prices
were ranged from 0.58 to 5.02 times the IRP for para-
cetamol suppository and ceftriaxone injection respect-
ively. Half of the lowest priced medicines were priced at
1.23 (25th percentile) to 2.07 (75th percentile) times the
IRP in the private sector, showing moderate variation in
medicine price ratios across individual lowest priced
medicines.
Highest priced medicines were found in less than four
drug outlets of public sector. So, we did not calculate
their MPR. But in the private sector, their MPR were
3.01 times IRP.
Comparison of costs in the public and private sectors
To compare patient prices across sectors, we used
twelve (n = 12) lowest priced medicines found in at least
four drug outlets in both public and private sectors, and
we calculated their MPR as depicted in Fig. 1. Except for
paracetamol suppository which had similar MPR in both
public and private sectors, MPR were moderately higher
in the private sector compared to the public sector but
substantially higher for ceftriaxone injection. Median
price ratios for these medicines were 1.18 and 1.61 in
the public and private sector respectively; patient prices
were 36 % times higher in the private sector than in the
public sector.
Affordability of medicines for standard treatment
regimens
As shown in Table 4, 70 % (7/10) of treatments of com-
mon childhood diseases prevalent in the zone with
standard treatment [27] were unaffordable, as they cost
a day’s wage or more days’ wages in both sectors. The
unaffordability of lowest priced medicines in the public
sector varies from 1.5 to 8.7 days’ wages. Treatments of
typhoid fever with chloramphenicol 1gm (8.7 days’
wages) and infections due to susceptible organism with
ceftriaxone 500 mg (5.8 days wages) cost more than 5
days’ wages, and they were the most unaffordable stand-
ard treatments in the public sector.
As shown in Table 4, the unaffordability of the lowest
priced medicines varies from 1.8 to 30.7 days’ wages in
the private sector. The most unaffordable standard treat-
ments were treatment of typhoid fever with chloramphe-
nicol1gm (10.2 days’ wages) and treatment of infections
due to susceptible organism with ceftriaxone 500 mg
(30.7 days’ wages).
Discussions
The findings of present study suggest that availability
of children’s EMs is below 50 % in both public sector
and private sector for both types of surveyed category
of medicines. The average availability of lowest priced
medicines for children is 43.0 % in the public and
42.8 % in the private sectors. Because of the general
incomparability of survey results (due to variation in
Table 3 Median price ratios of thirteen lowest priced medicines in the public and private sectors (n = 13)
Medicine name Lowest price medicines MPR (25th-75th percentile)
Public sector Private sector
Amoxicillin Suspension 125 mg 1.24(1.14–1.240) 2.07(1.87–2.07)
Amoxicillin Suspension 250 mg 1.47(1.34–1.54) 1.67(1.67– 1.89)
Amoxicillin- Clav Suspension 125 mg 0.62(0.48–0.98) 1.52(1.42–1.52)
Amoxicillin- Clav Suspension 250 mg N/A 1.05(0.91–1.11)
Chloramphenicol 1 gm vial 0.93(0.86–1.10) 1.10(1.10–1.10)
Ceftriaxone 500 mg vial 0.95(0.89 – 1.03) 5.02(4.47–5.02)
Cotrimoxazole 40 mg + 200 mg/5 ml Suspension 1.20(1.20–1.40) 1.49(1.40–1.59)
ORS to make 1000 ml soln. 1.53(1.15– 1.93) 2.55(1.78–2.55)
Paracetamol 120 mg/5 ml Syrup 1.17(0.90–1.32) 1.23(0.87–1.47)
Paracetamol 125 mg Suppository 0.58(0.49–0.59) 0.58(0.58–0.93)
Penicillin G 1 million IU 2.86(2.05–3.31) 3.15(2.84–3.15)
Procaine Penicillin G 4million IU 1.27(1.14–1.41) 1.84(1.63 – 2.04)
Salbutamol 100 mcg/dose inhaler 0.80(0.80–1.00) 1.54(1.16– 10.27)
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medicine pricing policy, methodology, types of preva-
lent disease, and medicine supply systems), it is diffi-
cult to make a comparative analysis of medicines
availability. However, these findings are consistent
with findings of study conducted by Anson et al. [10]
in Guatemala which reported 46 % in public sector
and 35 % in private sector. In contrast to the study
conducted by Wang et al. [16] in China, this finding
showed higher availability of lowest priced medicines
in both public and private sectors, but it showed
lower availability of highest priced medicines in both
public and private sectors. The study also revealed
that availability of medicines was higher in the public
sector than in the private sector. This finding is also
consistent with findings of studies conducted by
Anson et al. [10] and Wang et al. [16].
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Fig. 1 Comparison of MPR of lowest price medicines found in atleast four drug outlets in public and private sectors
Table 4 Affordability: number of days' wage of lowest paid unskilled government worker makes to purchase standard treatments
Conditions Drug name, strength, dosage form Treatment schedule Days wages to pay for
treatment
Public sector Private sector
Typhoid fever Chloramphenicol 1gm vial 25 mg/kg * 14.5 kg every 6 hours P.O. for
14 days = 20300 mg = 20.3gm 21vial [26].
8.7 10.2
Asthma Salbutamol 100 mcg/dose inhaler 1 inhaler of 200doses [27]. 1.5 2.9
Dysentery Cotrimoxazole 40 mg + 200 mg/5 ml
Suspension
24 mg/kg * 14.5 kg BID for 5 days = 3480 mg.72.5 ml
total for five days [27].
0.4 0.5
Severe Pneumonia Penicillin G 1 million IU vial 50 000 units/kg a14.5 kg IV every 4 hours for at
least 3 days = 13.05 millions of IU = 14vial for
three days [27].
3.1 3.4
Acute otitis media Amoxicillin 250 mg/5 ml Suspension 250 mg/5 ml P.O. TID for 10 days for children
above 6 years of age = 150 ml [27].
1.6 1.8
Acute rhinosinusitis Amoxicillin- Clav 156 mg/5 ml 156 mg/5 ml P.O. TID for 10dys = 150 ml [27]. 2.5 5.9
Acute bacterial tonsillitis Amoxicillin- Clav 156 mg/5 ml 156 mg/5 ml P.O. BID for ten days = 150 ml [27]. 2.5 5.9
Dehydration ORS to make 1litre Moderate dehydration 75 ml/kg * 14.5 = 1087.5 [27]. 0.3 0.5
Infections due to
susceptible organism
Ceftriaxone 500 mg vial Child under 50 kg maximum 1gm for 7 days [27]. 5.8 30.7
Pain/managenment Paracetamol 125 mg/5 ml
Suspension
5 year old child: 15 mg/kg*14.5 kg*4*3 = 104.4 ml [27]. 0.8 0.8
*Weight of average 5 year old child in Ethiopia = 14.5 kg [13, 34]
P.O. per oral, BID two times per a day, TID three times per a day
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When we compare availability of medicines for chil-
dren and for adults (or for overall population) perspec-
tive, the finding is lower than the finding of Abiye and
his colleagues study in the western part of Ethiopia for
public drug outlets [18]. But it is consistent for private
sector and higher for public sector compared with find-
ings of study conducted by Babar et al. [27] in Malaysia.
It is also similar for public sector and lower for private
sector from the findings reported by Bazargani et al.
[29]. In opposite to the current findings, availability of
medicines was higher in the private sector as compared
to the public sector for mixed or general populations
[28, 29]. The low availability of medicines in the formu-
lations preferable for use in children may limit access of
medicines to children. To tackle this problem, health
care professionals particularly pharmacists and nurses
calculate the dose from adult dosage. This calculation
may lead to incorrect dose use which might cause ad-
verse drug effect [30].
EMs used for the treatment of chronic diseases in chil-
dren were hardly found. This very low availability of
medicines for treatment of chronic diseases in children
consistent with government policy which is more fo-
cuses on the prevention rather than treatment [31].
Medicines offered free of charge from public sector are
not available in any private sector and even their avail-
ability in public sector is low which may cause the
inaccessibility of EMs for children. Though the most
common causes of child morbidity and mortality are
infectious diseases [13, 31], medicines used to treat com-
mon infectious disease in children like gentamicin is also
not available in any drug outlets in both public and pri-
vate sectors. This unavailability of common medicines
for treatment of infectious diseases in the children might
be due to lack of focuses from the government policy.
Like adult medications, the availability of child specific
lowest priced medicines far exceeded that of highest
priced medicines across all drug outlets in the public and
private sectors. Highest priced medicines are unavailable
in the 98.8 % of public sector drug outlets. This may be
due to generic procurement promotion in the public drug
outlets. The availability of lowest price medicines in the
drug outlets ranges from 5 to 45 % in both public and
private sectors. This is consistent with findings of study
conducted by Robertson et al. [17] and his colleagues even
though the perspective of study is not same.
The study also revealed that lowest priced medicines
for children in both public and private sectors were sold
at higher price than IRP. In the public sector, they are
sold at 1.18 times their IRP and 1.54 times their IRP in
the private sector. This finding is similar with the study
conducted on the prices, availability and affordability
of medicine in China [11] and findings of a study
conducted by Cameron et al. and his colleague [32].
There was a notable variability in prices across drug out-
lets in private sector. This finding is consistent with
study conducted on the availability, prices and afford-
ability of essential medicines in Haiti [26]. The variability
of price across the drug outlets in private sector might
be the result of high market competition.
Lowest priced medicines are unaffordable for 70 % of
standard treatments of prevalent infectious diseases in
both sectors as they cost a day’s wage or more days’
wages for lowest paid government employee. However,
the extent they cost varies between the public and pri-
vate drug outlets. This finding is consistent with the
findings from study done on the availability, prices and
affordability of the World Health Organization’s essential
medicines for children in Guatemala [10]. These costs
do not include the costs of consultation and diagnostic
tests, so that families who need medicines for more
than one child may be confronted with more costs and
extra days’ wages. These findings are inconsistent with
other studies of affordability of adult medicines which
showed unaffordability of chronic medicines rather
than drugs for infectious treatment for low income
populations [10, 29] and consistent with study of af-
fordability in the Haiti [26].
Although Ethiopia achieved Millennium Development
Goal for reducing child mortality rate 2 years ahead of 2015
[33], the findings from this study suggest that accessibility
of EMs for children is still low. Therefore, there is a need of
improving the access to EMs for children which will help
the country to achieve the global strategy for every child as
part of the Sustainable Development Goals.
Limitation of the study
This study did not assess the medicine procurement
prices and it was also conducted in the one zone due to
logistical constraints.
Conclusion
This study was conducted to assess access to essential
medicines for children based on their availability, price,
and affordability. It has shown that availability of EMs
for children use was below the recommended average in
both public and private sectors. But the unavailability of
EMs offered free of charge from public sector was press-
ing problem. Medicines were sold at higher price of IRPs
and were unaffordable for people with low income in
both public and private sectors.
The findings of this study suggest that access to EMs
to children is hampered by low availability and high
price which is unaffordability. Thus, further study should
be conducted on larger scale by including medicines
procurement price to identify acute areas for policy
interventions such as price and or supply to enhance ac-
cess to EMs to children.
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